Prolia (Denosumab) Cost in Alabama: Pricing, Insurance, and Savings Options for 2026

What Prolia (Denosumab) Costs at Alabama Pharmacies in 2026

The cash-pay price for a single 60 mg prefilled syringe of Prolia averages $1,500 across Alabama retail pharmacies in 2026, matching Amgen's national list price. Because the drug is administered as a subcutaneous injection every six months, a patient paying entirely out of pocket faces roughly $3,000 per year before any discounts or assistance programs.

Why the Price Stays High

Denosumab is a fully human monoclonal antibody targeting RANK ligand, and no FDA-approved biosimilar has reached the U.S. Market as of mid-2026. Amgen holds the originator biologic license, and without biosimilar competition, retail pricing has remained stable near the list price for several consecutive years. The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every six months reduced the incidence of new vertebral fractures by 68% over 36 months compared to placebo [1]. That efficacy profile supports formulary inclusion by most payers, but it does not drive the cash price down.

Retail Pharmacy Price Variation

Prices at Alabama chain pharmacies (CVS, Walgreens, Walmart) cluster tightly around the $1,500 mark. Independent pharmacies may charge slightly less or more depending on wholesaler contracts. Patients should request a price quote before filling, since specialty pharmacies sometimes apply different markups. GoodRx and similar aggregators occasionally show modest discounts in the $1,350 to $1,450 range for Alabama ZIP codes, but availability fluctuates.

Alabama Medicaid and Prolia Coverage

Alabama Medicaid does not cover Prolia (denosumab) for osteoporosis as of 2026. This exclusion applies to the standard fee-for-service Medicaid program and the Alabama Coordinated Health Network managed care plans.

What the Exclusion Means in Practice

Patients enrolled in Alabama Medicaid who need antiresorptive therapy are typically directed toward generic oral bisphosphonates such as alendronate (generic Fosamax) or risedronate, which are covered under the state's preferred drug list. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend denosumab as a first-line option for postmenopausal osteoporosis alongside bisphosphonates [2], but Medicaid formulary decisions in Alabama prioritize lower-cost alternatives.

Appeals and Exceptions

Medicaid beneficiaries who have documented intolerance or contraindications to oral bisphosphonates (e.g., esophageal stricture, severe GERD refractory to management, or inability to remain upright for 30 minutes) can file a prior authorization exception request. Approval rates for these exceptions are not publicly reported by the Alabama Medicaid Agency, and anecdotal reports from prescribers suggest the process requires detailed clinical documentation including a trial-and-failure history with at least one oral agent.

Medicare Part B Coverage in Alabama

Most Medicare beneficiaries in Alabama can access Prolia through Part B, not Part D. Denosumab administered by a healthcare provider in an office or clinic setting falls under Medicare Part B's "incident to" physician services benefit.

Cost-Sharing Under Part B

After the Part B deductible ($257 in 2026), Medicare covers 80% of the approved amount. The patient's 20% coinsurance on a $1,500 injection is approximately $300 per dose, or $600 per year. A Medigap supplement plan (Plans C, F, or G, depending on enrollment date) typically covers this coinsurance in full. Medicare Advantage plans in Alabama (Blue Cross Blue Shield of Alabama, UnitedHealthcare, Humana) cover Prolia under their medical benefit, though copay structures and prior authorization requirements vary by plan.

Step Therapy Requirements

Some Medicare Advantage plans in Alabama require step therapy, meaning the patient must try and fail an oral bisphosphonate before the plan approves denosumab. The Endocrine Society's 2020 Clinical Practice Guideline identifies denosumab as appropriate first-line treatment for patients at high fracture risk [3], and this guideline language can support appeals against step therapy denials.

Commercial Insurance Coverage in Alabama

Blue Cross Blue Shield of Alabama (BCBS-AL), the dominant commercial insurer in the state, covers Prolia on its specialty drug formulary with prior authorization for postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and bone loss in patients receiving androgen deprivation or aromatase inhibitor therapy.

Typical Out-of-Pocket Costs

Commercially insured patients in Alabama generally pay between $0 and $300 per injection depending on plan design. Plans with specialty drug tiers may assign a 20% to 30% coinsurance, which on a $1,500 drug translates to $300 to $450 before any manufacturer assistance. Plans with flat specialty copays often cap the cost at $75 to $150 per fill. Patients should confirm whether their plan classifies Prolia under the medical benefit (administered in-office) or the pharmacy benefit (self-administered at home), because cost-sharing rules differ.

Other Alabama Commercial Payers

UnitedHealthcare, Cigna, Aetna, and Humana commercial plans sold in Alabama each maintain their own formulary placement for denosumab. Coverage is near-universal for the osteoporosis indication with prior authorization, but tier placement and coinsurance percentages vary. Patients switching plans during open enrollment should verify Prolia's tier status in the Summary of Benefits before finalizing a selection.

The Amgen Prolia Savings Card

Amgen offers the Prolia Complete savings card, which reduces out-of-pocket costs for commercially insured patients. The card covers up to $1,800 in copay or coinsurance costs per calendar year. That amount is sufficient to offset most or all patient responsibility for two injections annually.

Eligibility Rules

The card is available to patients with commercial insurance who are not enrolled in any federal or state healthcare program (Medicare, Medicaid, TRICARE, VA). Alabama residents with employer-sponsored or ACA marketplace plans qualify. Enrollment is free and can be completed online or by phone through the Prolia Complete program.

How to Use the Card in Alabama

Patients present the savings card at the provider's office or specialty pharmacy at the time of injection. The provider bills the patient's insurance first, and the savings card covers the remaining copay or coinsurance up to the annual limit. If the injection is administered in-office and billed under the medical benefit, the provider's billing staff submits a coordination of benefits with the savings card information. Patients should bring the card to every appointment, not just the first.

Compounded Denosumab in Alabama

Compounded denosumab is legally available in Alabama through 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on valid individual prescriptions.

What "Compounded Denosumab" Means

A 503A pharmacy can prepare a denosumab formulation from bulk pharmaceutical-grade ingredients when a prescriber writes a patient-specific prescription. These preparations are not FDA-approved products and do not carry the Prolia brand name. The compounded version may differ in formulation, concentration, or excipients from the Amgen product.

Pricing and Availability

Compounded denosumab pricing from Alabama 503A pharmacies has been reported at significantly lower cost points than the branded product. However, patients should understand that compounded biologics carry different quality assurance profiles than manufactured products. The FDA has issued guidance on compounding that distinguishes between 503A patient-specific compounding and 503B outsourcing facilities [4]. Alabama's Board of Pharmacy regulates 503A pharmacies within the state, and patients should confirm that any compounding pharmacy holds a current Alabama license.

Clinical Considerations

Denosumab is a monoclonal antibody with a molecular weight of approximately 147 kDa. Biologics of this complexity are difficult to replicate outside of controlled manufacturing environments. The FREEDOM extension study followed patients for up to 10 years and demonstrated sustained fracture risk reduction with continued Amgen-manufactured denosumab [5]. No comparable long-term data exist for compounded formulations. Prescribers in Alabama who consider compounded denosumab should weigh the cost savings against the absence of bioequivalence data.

Dr. Michael McClung, a principal investigator in the FREEDOM trial, has stated: "Discontinuation of denosumab leads to rapid bone loss and increased vertebral fracture risk, so any decision about the formulation used must account for the patient's ability to continue uninterrupted therapy" [5].

Telehealth Prescribing for Prolia in Alabama

Alabama permits telehealth prescribing of Prolia (denosumab). A licensed physician or qualified prescriber can evaluate a patient via video visit and write a prescription for denosumab. The Alabama Board of Medical Examiners recognizes telehealth encounters as valid for establishing or continuing a prescriber-patient relationship under the Alabama Telehealth Act.

Practical Workflow

The telehealth prescriber orders or reviews a current DXA scan and relevant labs (serum calcium, 25-hydroxyvitamin D, renal function). If denosumab is appropriate, the prescriber sends the prescription to a specialty pharmacy or arranges an in-office injection appointment with a local provider. The injection itself requires a healthcare professional to administer, so telehealth handles the evaluation and prescribing while a separate visit handles administration. Some Alabama patients combine telehealth prescribing with a local infusion center or provider who administers the injection per the telehealth prescriber's order.

How to Reduce Prolia Costs in Alabama

Several strategies can lower out-of-pocket costs for Alabama patients who need denosumab.

Step 1: Verify Insurance Benefit Design

Call the number on the back of your insurance card and ask specifically whether Prolia is covered under your medical benefit or pharmacy benefit, what prior authorization documentation your plan requires, and what your coinsurance or copay will be after the plan's negotiated rate is applied.

Step 2: Apply the Amgen Savings Card

If you have commercial insurance and no federal coverage, enroll in the Prolia Complete program before your next injection. The card covers up to $1,800 per year.

Step 3: Explore Patient Assistance

Amgen's Safety Net Foundation provides free Prolia to patients who are uninsured or underinsured and meet income criteria (generally at or below 300% of the federal poverty level). Alabama residents can apply through the foundation's website or by calling 1-888-762-6436.

Step 4: Compare Specialty Pharmacy Pricing

Specialty pharmacies such as Accredo, BriovaRx, and AllianceRx Walgreens may offer different pricing than retail locations. Some also coordinate benefits with manufacturer savings programs automatically.

The National Osteoporosis Foundation (now Bone Health & Osteoporosis Foundation) estimates that osteoporotic fractures cost the U.S. Healthcare system $19 billion annually [6], making prevention with agents like denosumab a cost-effective strategy over the long term even at current drug prices.

Safety Monitoring While on Prolia

Alabama patients starting denosumab should have baseline serum calcium and 25-hydroxyvitamin D levels checked before the first injection. Hypocalcemia is the most clinically significant adverse effect, occurring in approximately 2% of patients in the Prolia prescribing information [7].

Ongoing Lab Work

Serum calcium should be rechecked within 2 weeks of each injection in patients with renal impairment (CrCl <30 mL/min) or other risk factors for hypocalcemia. All patients should take supplemental calcium (1,000 mg daily) and vitamin D (at least 1,000 IU daily) unless contraindicated. DXA scans are typically repeated every 2 years to assess treatment response, consistent with ISCD 2019 Official Positions [8].

Discontinuation Risk

Stopping denosumab without transitioning to another antiresorptive agent causes rapid bone mineral density loss and a rebound increase in vertebral fracture risk. A 2017 analysis published in the Journal of Bone and Mineral Research found that vertebral fracture incidence after denosumab discontinuation was 7.1%, compared to 0.8% during continued treatment [9]. Alabama prescribers should plan a transition to an oral or IV bisphosphonate if denosumab is stopped.

The AACE guideline authors wrote: "Patients discontinuing denosumab should receive a bisphosphonate to mitigate rebound bone loss, ideally initiated within 6 months of the last denosumab injection" [2].